Experienced in Alveolar Soft Part Sarcoma

Dr. Zhonglin Y. Hao

Oncology | Hematology Oncology | Hematology
Kentucky Medical Services Foundation, Inc
100 Greatstone Pt, 
Lexington, KY 
Experienced in Alveolar Soft Part Sarcoma
Kentucky Medical Services Foundation, Inc
100 Greatstone Pt, 
Lexington, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zhonglin Hao is an Oncologist and a Hematologist Oncology provider in Lexington, Kentucky. Dr. Hao is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in KY
Hospital Affiliations
University Of Kentucky Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

KENTUCKY MEDICAL SERVICES FOUNDATION, INC
100 Greatstone Pt, Lexington, KY 40504
Other Locations
KENTUCKY MEDICAL SERVICES FOUNDATION, INC
800 Rose St, Lexington, KY 40536
KENTUCKY MEDICAL SERVICES FOUNDATION, INC
2400 Greatstone Pt, Lexington, KY 40504

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer
A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Procedure
Study Drugs: Osimertinib, Telaglenastat Hydrochloride
Study Phase: Phase 1/Phase 2
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Topotecan Hydrochloride
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Savolitinib
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

46 Total Publications

A machine learning model exploring creep performance of dental composites.
A machine learning model exploring creep performance of dental composites.
Journal: Dental materials : official publication of the Academy of Dental Materials
Published: February 06, 2025
Similar Doctors
Advanced in Alveolar Soft Part Sarcoma
Dr. Vikas K. Singh
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Vikas K. Singh
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

4003 Kresge Way, 
Louisville, KY 
 (61.1 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vikas Singh is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Lymphofollicular Hyperplasia, Adult Soft Tissue Sarcoma, Bone Tumor, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Singh is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Reema A. Patel
Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Reema A. Patel
Oncology

Kentucky Medical Services Foundation, Inc

740 S Limestone St, 
Lexington, KY 
 (2.5 miles away)
859-257-8562
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reema Patel is an Oncologist in Lexington, Kentucky. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Gastrointestinal Stromal Tumor, and Undifferentiated Pleomorphic Sarcoma.

Experienced in Alveolar Soft Part Sarcoma
Dr. Patrick A. Williams
Oncology | Hematology Oncology | Hematology
Experienced in Alveolar Soft Part Sarcoma
Dr. Patrick A. Williams
Oncology | Hematology Oncology | Hematology

Flaget Healthcare Inc

4359 New Shepherdsville Rd, Unit 100, 
Bardstown, KY 
 (54.1 miles away)
502-350-5700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Williams is an Oncologist and a Hematologist Oncology provider in Bardstown, Kentucky. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Williams is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hao's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile